572 related articles for article (PubMed ID: 24597466)
1. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U; Shear NH; Rieder MJ; Hwang S; Fung V; Nakamura H; Connolly MB; Ito S; Carleton BC;
Epilepsia; 2014 Apr; 55(4):496-506. PubMed ID: 24597466
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs.
Neuman MG; Cohen L; Nanau RM; Hwang PA
Transl Res; 2012 May; 159(5):397-406. PubMed ID: 22500513
[TBL] [Abstract][Full Text] [Related]
4. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.
Amstutz U; Ross CJ; Castro-Pastrana LI; Rieder MJ; Shear NH; Hayden MR; Carleton BC;
Clin Pharmacol Ther; 2013 Jul; 94(1):142-9. PubMed ID: 23588310
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
[TBL] [Abstract][Full Text] [Related]
6. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
[TBL] [Abstract][Full Text] [Related]
7. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.
Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI
J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464
[TBL] [Abstract][Full Text] [Related]
8. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Hung SI; Chung WH; Jee SH; Chen WC; Chang YT; Lee WR; Hu SL; Wu MT; Chen GS; Wong TW; Hsiao PF; Chen WH; Shih HY; Fang WH; Wei CY; Lou YH; Huang YL; Lin JJ; Chen YT
Pharmacogenet Genomics; 2006 Apr; 16(4):297-306. PubMed ID: 16538176
[TBL] [Abstract][Full Text] [Related]
9. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.
Wei CY; Chung WH; Huang HW; Chen YT; Hung SI
J Allergy Clin Immunol; 2012 Jun; 129(6):1562-9.e5. PubMed ID: 22322005
[TBL] [Abstract][Full Text] [Related]
10. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.
Chong KW; Chan DW; Cheung YB; Ching LK; Hie SL; Thomas T; Ling S; Tan EC
Arch Dis Child; 2014 Jun; 99(6):581-4. PubMed ID: 24225276
[TBL] [Abstract][Full Text] [Related]
11. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?
Shi YW; Min FL; Qin B; Zou X; Liu XR; Gao MM; Wang Q; Zhou JQ; Liao WP
Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):58-64. PubMed ID: 22348435
[TBL] [Abstract][Full Text] [Related]
12. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.
Chang CC; Too CL; Murad S; Hussein SH
Int J Dermatol; 2011 Feb; 50(2):221-4. PubMed ID: 21244392
[TBL] [Abstract][Full Text] [Related]
13. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.
Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Chen P; Lin SY; Chen WH; Konyoung P; Khunarkornsiri U; Auvichayapat N; Pavakul K; Kulkantrakorn K; Choonhakarn C; Phonhiamhan S; Piyatrakul N; Aungaree T; Pongpakdee S; Yodnopaglaw P
Epilepsia; 2010 May; 51(5):926-30. PubMed ID: 20345939
[TBL] [Abstract][Full Text] [Related]
14. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China.
Wu XT; Hu FY; An DM; Yan B; Jiang X; Kwan P; Stefan H; Zhou D
Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111
[TBL] [Abstract][Full Text] [Related]
15. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand.
Tiamkao S; Jitpimolmard J; Sawanyawisuth K; Jitpimolmard S
Int J Clin Pharm; 2013 Aug; 35(4):608-12. PubMed ID: 23649893
[TBL] [Abstract][Full Text] [Related]
16. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China.
Sun D; Yu CH; Liu ZS; He XL; Hu JS; Wu GF; Mao B; Wu SH; Xiang HH
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):146-150. PubMed ID: 24496695
[TBL] [Abstract][Full Text] [Related]
17. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report.
Lin LC; Lai PC; Yang SF; Yang RC
Kaohsiung J Med Sci; 2009 Feb; 25(2):82-6. PubMed ID: 19321411
[TBL] [Abstract][Full Text] [Related]
18. Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.
He XJ; Jian LY; He XL; Wu Y; Xu YY; Sun XJ; Miao LY; Zhao LM
Pharmacol Rep; 2013; 65(5):1256-62. PubMed ID: 24399721
[TBL] [Abstract][Full Text] [Related]
19. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.
Wang Q; Zhou JQ; Zhou LM; Chen ZY; Fang ZY; Chen SD; Yang LB; Cai XD; Dai QL; Hong H; Wang HX
Seizure; 2011 Jul; 20(6):446-8. PubMed ID: 21397523
[TBL] [Abstract][Full Text] [Related]
20. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients.
Zhang Y; Wang J; Zhao LM; Peng W; Shen GQ; Xue L; Zheng XX; He XJ; Gong CY; Miao LY
Eur J Clin Pharmacol; 2011 Sep; 67(9):885-7. PubMed ID: 21424386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
